Transforming cancer treatment and advancing new therapies through empowered science.

Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to... 
Read more

NASDAQ | SGEN (Common Stock)

$43.16

 0.66 (1.55%)

High$43.57
Low$41.86
Volume970,601
Market Cap$5,390,116,921

05/28/15  4:00 p.m. ET

Minimum 20 minute delay

Latest Investor Information

Press Releases

Seattle Genetics Announces Clinical Data Presentations from Multiple Antibody-Drug Conjugate (ADC) Programs at ASCO Annual Meeting 05/28/15

Read more

Seattle Genetics Reports First Quarter 2015 Financial Results 04/30/15

Read more

Events

UBS Global Healthcare Conference05/19/15 2:00 p.m. ETView eventBank of America Merrill Lynch 2015 Health Care Conference05/14/15 10:40 a.m. PTView event
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources